BRAF and non-small cell lung carcinoma: Furthermore, another recent phase 2, multicenter, nonrandomized, open‐label study investigated the antitumor activity and safety of dabrafenib plus trametinib in patients with BRAF V600E‐mutant NSCLC 39.